Global Chronic Obstructive Pulmonary Disease (COPD) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035
Global
Chronic Obstructive Pulmonary Disease (COPD) Market Outlook
Thelansis’s “Global Chronic
Obstructive Pulmonary Disease (COPD) Market Outlook, Epidemiology, Competitive
Landscape, and Market Forecast Report (Top 32 Markets) – 2025 To 2035″ covers
disease overview, epidemiology, kidney biopsy cases, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Chronic
Obstructive Pulmonary Disease (COPD) treatment modalities options for the
32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South /
Latin America).
Global Chronic
Obstructive Pulmonary Disease (COPD) Overview
Chronic
Obstructive Pulmonary Disease (COPD) is a significant global contributor to
chronic illness and premature death. As the third leading cause of death
worldwide, its prevalence and fatality rates are projected to rise in the
coming decades. The disease is characterized by chronic inflammation that
causes structural alterations and constriction in the smaller air passages.
This inflammatory process also drives lung tissue damage, resulting in the
detachment of alveoli from smaller airways and a decrease in lung elasticity,
which ultimately reduces the airways’ ability to remain open during exhalation.
To assess the extent of airflow restriction, spirometry serves as the most
accessible and dependable measure of lung function, with diagnosis confirmed by
a post-bronchodilator FEV1/FVC ratio of less than 0.70. The clinical impact of
COPD on an individual is determined not only by the degree of airflow
limitation but also by the severity of associated symptoms and the frequency of
exacerbations. Because an imperfect correlation exists between the degree of
airflow limitation and patient symptoms, modern staging acts as a practical
framework that combines spirometric grading with symptom burden and
exacerbation risk to guide the initial management plan.
Market Definition:
- North America
(United States, Canada)
- Europe
(Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany,
Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain,
Sweden, Switzerland, United Kingdom)
- Middle East
(Saudi Arabia, UAE, Kuwait, Turkey)
- Asia Pacific
(Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New
Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
- Africa (Egypt,
Nigeria, South Africa, Morocco)
- South / Latin
America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)
Insights driven by robust research, including:
- In-depth
interviews with leading KOLs and payers
- Physician
surveys
- RWE analysis
for claims and EHR datasets
- Secondary
research (e.g., peer-reviewed journal articles, third-party research
databases)
Deliverables format and updates*:
- Detailed Report
(PDF)
- Market Forecast
Model (MS Excel-based automated dashboard)
- Epidemiology
(MS Excel; interactive tool)
- Executive
Insights (PowerPoint presentation)
- Others: regular
updates, customizations, consultant support
*As per Thelansis’s policy, we ensure that we include all the recent
updates before releasing the report content and market model.
Salient features of Market Forecast model:
- 10-year market
forecast (2025–2035)
- Bottom-up
patient-based market forecasts validated through the top-down sales
methodology
- Covers
clinically and commercially-relevant patient populations/ line of
therapies
- Annualized
drug-level sales and patient share projections
- Utilizes our
proprietary Epilansis and Analog tool (e.g.,
drug uptake and erosion) datasets and conjoint analysis approach
- Detailed
methodology/sources & assumptions
- Graphical and
tabular outputs
- Users can
customize the model based on requirements
Key business questions answered:
- How can drug
development and lifecycle management strategies be optimized across the 32
markets (North America, Europe, Middle East, Asia Pacific, Africa, South /
Latin America)?
- How large is
the patient population in terms of incidence, prevalence, segments, and
those receiving drug treatments?
- What is the
10-year market outlook for sales and patient share?
- Which events
will have the greatest impact on the market’s trajectory?
- What insights
do interviewed experts provide on current and emerging treatments?
- Which pipeline
products show the most promise, and what is their potential for launch and
future positioning?
- What are the
key unmet needs and KOL expectations for target profiles?
- What key
regulatory and payer requirements must be met to secure drug approval and
favorable market access?
- and more…
Comments
Post a Comment